Skip to main content
Erschienen in: Journal of Neurology 8/2016

Open Access 22.06.2016 | Letter to the Editors

l-Arginine intervention at hyper-acute phase protects the prolonged MRI abnormality in MELAS

verfasst von: Miyuki Kitamura, Shuichi Yatsuga, Toshi Abe, Nataliya Povalko, Reo Saiki, Kikumi Ushijima, Yushiro Yamashita, Yasutoshi Koga

Erschienen in: Journal of Neurology | Ausgabe 8/2016

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Dear Sirs,
Though neurological signs in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) resemble features of ischemic stroke. According to the limited analyses, recurrent strokes are associated with vasogenic edema by diffusion weighted image (DWI) on magnetic resonance image (MRI) [1, 2]. Endothelial dysfunction has been found in MELAS [3], and l-arginine, a potent donor of nitric oxide at physiological condition, has been used as a therapeutic purpose [4]. In this study, we evaluate the therapeutic effects of l-arginine infusion at super-acute phase of stroke-like episodes (SLE) on the clinical and the serial neuroimaging analysis in two MELAS patients.
Patient 1 is a 7-year-old girl who was diagnosed as MELAS based on a finding of symptoms and 79 % mutation of an A3243G in the mitochondrial DNA in urine. She has a history of SLE at the age of 5.5 years-old. She complained of the sudden headache, vomit, hemi-convulsion and hemianopia in the left side. After getting the written informed consent (Kurume University IRB#9715), we infused 0.5 g/kg/dose of l-arginine within 60 min after the onset and took the brain MRI at 18 h from the onset. All of clinical symptoms disappeared within 30 min after l-arginine infusion without using anti-convulsants. The series of MRIs were performed till 6 month from the onset of stroke-like episodes. MRI obtained at 18 h after the onset showed high intensity signal in T2WI, and DWI and low in ADC in right and left hemisphere of cerebrum and right occipital region. However those abnormal findings completely normalized on MRIs at 7 days and 1 month later.
Patient 2 is a 32-year-old girl who fulfilled the diagnostic criteria of MELAS and has a 45 % mutation of A3243G in urine. She has history of two SLE and was then followed as MELAS. She complained of the sudden onset of left-hemi-convulsion, severe headache, and vomit. After getting informed consent, she was infused with 0.5 g/kg/dose of l-arginine at 60 min after the onset, and then the series of brain MRI were taken. Hemi-convulsion was getting worse to generalized convulsion, however the seizures and vomit disappeared within 120 min after l-arginine infusion followed by using anti-convulsants. MRI obtained at 2 and 9 h after the onset showed high intensity on T2WI and DWI and low ADC in right parietal lobe. However those abnormal findings completely normalized in MRI at 1 week and 1 month later as shown in Fig. 1.
Abnormal MRI region in superficial layers of cortex showed low ADC with high intensity on DWI suggested cytotoxic edema. Meanwhile, adjacent subcortical white matter that showed high ADC and high intensity on DWI suggested vasogenic edema. The follow up MRIs in two MELAS patients showed no abnormal signal or atrophic change in 7 days and in 1 month after the onset of SLE. Since MRI abnormality seen in MELAS usually lasting several months after the SLE [5], l-arginine infusion at hyperacute phase may prevents the prolonged change of MRI in our two patients. Though MRI abnormalities seen in our patients cannot be ruled out completely by the results of neuronal hyper-excitability, current episodes are the typical and the same as their previous SLE evident by prolonged changes in MRI. We speculate that l-arginine may protect neuron in cortex from permanent cell death, by improving either regional microcirculation of cerebral blood flow [3, 4], permeability of BBB, or interaction by astrocyte–neuron coupling which controls the cerebral circulation [2, 6].
Our data indicated that l-arginine infusion during the hyperacute phase of SLE in MELAS may significantly improve the symptoms, and also completely protect the progression of neuroimaging change from transient to permanent brain atrophy.

Compliance with ethical standards

Funding

All phases of this study were supported by Grants #16390308 (Y.K.) from the Ministry of Culture and Education of Japan, as well as #CCT-B-1803 (Y.K.) from Evidence-based Medicine, Ministry of Health, Labor and Welfare of Japan, as well as Grants-in-Aid of the Research on Intractable Diseases, and in part, by grant from AMED #16ek0109088h0002. (Y.K.) from the Ministry of Health, Labor and Welfare of Japan.

Conflicts of interest

The authors have no conflicts of interest to disclose.

Ethical standard

The study protocol was approved by ethics commitees at the Kurume University (Kurume University IRB#9715). All patients or parents of the patient gaved informed consents and comprehend the information, provided written informed consent.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Neuer Inhalt

e.Med Neurologie & Psychiatrie

Kombi-Abonnement

Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

Weitere Produktempfehlungen anzeigen
Literatur
1.
Zurück zum Zitat Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP (1984) Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 16:481–488. doi:10.1002/ana.410160409 CrossRefPubMed Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP (1984) Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 16:481–488. doi:10.​1002/​ana.​410160409 CrossRefPubMed
3.
Zurück zum Zitat Iizuka T, Sakai F (2010) Pathophysiology of stroke-like episodes in MELAS: neuron–astrocyte uncoupling in neuronal hyperexcitability. Future Neurol 5:61–83. doi:10.2217/fnl.09.71 CrossRef Iizuka T, Sakai F (2010) Pathophysiology of stroke-like episodes in MELAS: neuron–astrocyte uncoupling in neuronal hyperexcitability. Future Neurol 5:61–83. doi:10.​2217/​fnl.​09.​71 CrossRef
Metadaten
Titel
l-Arginine intervention at hyper-acute phase protects the prolonged MRI abnormality in MELAS
verfasst von
Miyuki Kitamura
Shuichi Yatsuga
Toshi Abe
Nataliya Povalko
Reo Saiki
Kikumi Ushijima
Yushiro Yamashita
Yasutoshi Koga
Publikationsdatum
22.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 8/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8069-4

Weitere Artikel der Ausgabe 8/2016

Journal of Neurology 8/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.